Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine.

Tumor cell resistance to certain chemotherapeutic agents may result in cross-resistance to related antineoplastic agents. To study cross-resistance among inhibitors of ribonucleotide reductase, we developed hydroxyurea-resistant (HU-R) CCRF-CEM cells. These cells were 6-fold more resistant to hydroxyurea than the parent hydroxyurea-sensitive (HU-S) cell line and displayed an increase in the mRNA and protein of the R2 subunit of ribonucleotide reductase. We examined whether HU-R cells were cross-resistant to gemcitabine, a drug that blocks cell proliferation by inhibiting ribonucleotide reductase and incorporating itself into DNA. Contrary to our expectation, HU-R cells had an increased sensitivity to gemcitabine. The IC50 of gemcitabine was 0.061 +/- 0.03 microM for HU-R cells versus 0.16 +/- 0.02 microM for HU-S cells (P = 0.005). The cellular uptake of [3H]gemcitabine and its incorporation into DNA were increased in HU-R cells. Over an 18-h incubation with radiolabeled gemcitabine (0.25 microM), gemcitabine uptake was 286 +/- 37.3 fmol/10(6) cells for HU-R cells and 128 +/- 8.8 fmol/10(6) cells for HU-S cells (P = 0.03). The incorporation of gemcitabine into DNA was 75 +/- 6.7 fmol/10(6) cells for HU-R cells versus 22 +/- 0.6 fmol/10(6) cells for HU-S cells (P < 0.02). Our studies suggest that the increased sensitivity of HU-R cells to gemcitabine results from increased drug uptake by these cells. This, in turn, favors the incorporation of gemcitabine into DNA, resulting in enhanced cytotoxicity. The increased sensitivity of malignant cells to gemcitabine after the development of hydroxyurea resistance may be relevant to the design of chemotherapeutic trials with these drugs.

[1]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[2]  M. Michael,et al.  Clinical experience with gemcitabine in pancreatic carcinoma. , 1997, Oncology.

[3]  W. Taylor,et al.  Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. , 1997, Cancer research.

[4]  T. Kinsella,et al.  Overexpression of a hexa-histidine and T7 peptide-tagged human ribonucleotide reductase small subunit, R2 in Escherichia coli and the generation of human R2 antibodies. , 1997, International journal of oncology.

[5]  W. Plunkett,et al.  Gemcitabine: preclinical pharmacology and mechanisms of action. , 1996, Seminars in oncology.

[6]  T. Lawrence,et al.  Radiosensitization of human solid tumor cell lines with gemcitabine. , 1996, Seminars in oncology.

[7]  Y. Yen,et al.  Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. , 1995, Cancer research.

[8]  Y. Yen,et al.  Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. , 1994, Cancer research.

[9]  P. Reichard,et al.  From RNA to DNA, why so many ribonucleotide reductases? , 1993, Science.

[10]  C. Chitambar,et al.  Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. , 1990, Cancer research.

[11]  B. Chabner,et al.  Cancer Chemotherapy: Principles and Practice , 1990 .

[12]  Carter Gl,et al.  Cross-Resistance Patterns in Hydroxyurea-resistant Leukemia L1210 Cells , 1988 .

[13]  J. Wright,et al.  Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line. , 1987, Biochemistry.

[14]  J. Wright,et al.  Altered expression of ribonucleotide reductase and role ofM2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines , 1987, Somatic cell and molecular genetics.

[15]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[16]  A. Gräslund,et al.  Characterization of the free radical of mammalian ribonucleotide reductase. , 1982, The Journal of biological chemistry.

[17]  H. Lankinen,et al.  Overproduction of the free radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[19]  W. Plunkett,et al.  Metabolism of 9-β-d-Arabinofuranosyladenine by Mouse Fibroblasts , 1975 .

[20]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[21]  G. Schochetman,et al.  Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships. , 1967, Cancer research.

[22]  J. Carmichael,et al.  The role of gemcitabine in the treatment of other tumours. , 1998, British Journal of Cancer.

[23]  J. Ford.  Cancer Chemotherapy: Principles and Practice , 1991, The Yale Journal of Biology and Medicine.

[24]  J. G. Cory.  Ribonucleotide reductase as a chemotherapeutic target. , 1988, Advances in enzyme regulation.

[25]  G. L. Carter,et al.  Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells. , 1988, Cancer research.

[26]  J. G. Cory,et al.  Combination chemotherapy directed at the components of nucleoside diphosphate reductase. , 1985, Pharmacology & therapeutics.

[27]  Y. Cheng,et al.  Nature and properties of mammalian ribonucleoside diphosphate reductase. , 1984, Pharmacology & therapeutics.

[28]  P. Reichard,et al.  Reduction of ribonucleotides. , 1979, Annual review of biochemistry.